HEP-1
Aliases: Liver peptide bioregulator · Hepatoprotector peptide
Last verified: 2026-09-24
The short version
HEP-1 is the tip of the problematic 'bioregulator' iceberg: a name without a standardized substance. It is simultaneously sold as a liver extract and as a synthetic peptide, without a published sequence, without independent characterization, without a single human data point. For comparison: Epitalon at least has a clear sequence (Ala-Glu-Asp-Gly) and a molecule determined by name; 'HEP-1' is a category. The liver is not an organ to be 'regulated' by peptides of unknown structure — it would be a supremely ironic target for an uncontrolled experiment.
Identity & type
- Molecular type
- bioregulator
- Origin
- Insufficiently defined: 'HEP-1' is sold as a liver peptide extract or a synthetic analog depending on the source — two different things under one name.
Mechanism of action
A name used for peptides isolated from liver within the 'peptide bioregulator' program (Khavinson-adjacent); hepatoprotective action is claimed via modulation of hepatocyte cell cycles — published data on a concrete 'HEP-1' molecule are close to nonexistent.
not confirmed in humans
Dosing & routes
Official / clinical context
No official context exists.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Very rare; occasionally among users combining several 'bioregulators' in a course, without measured outcomes.
Unverified self-reports. Not medical advice. Not endorsement.
Protocol — official vs community
Official / label
No approved protocol exists, and no standardized human data of any kind exist for a concrete 'HEP-1' molecule.
Duration: —
A label used for liver-derived peptides in the Khavinson-adjacent program; published data on this specific compound are close to nonexistent.
Community (anecdotal)
Vendors list 1–5 mg SC or oral capsules modeled on the shared bioregulator course pattern.
- Cycle:
- 10–20 day courses, 1–2× per year, as extrapolated from the series.
- Break:
- Months between courses.
Nothing in this regimen is specific to HEP-1 — it is the generic bioregulator pattern with a liver label attached, and it sits outside the published literature entirely.
Human evidence
None.
Preclinical evidence
Unclear: it is attributed to the same family of studies as the other 'bioregulators' — one source, small samples, no replication.
Known risks
- Unknown substance = unknown riskstheoretical
- Delaying real hepatological treatment in liver diseasecharacterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Identity of the substance — the first and basic question
- Everything else — effect, dose, safety
Frequently asked questions
References
- Khavinson-adjacent liver peptide literature (single-source, small animal studies)